References
- Bartolucci R, Wei J, Sanchez JJ, et al (2009). XPG mRNA expression levels modulate prognosis in resected non-smallcell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin Lung Cancer, 10, 47-52. https://doi.org/10.3816/CLC.2009.n.007
- Cobo M, Isla D, Massuti B, et al (2007). Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol, 25, 2747-54. https://doi.org/10.1200/JCO.2006.09.7915
- Dimoudis S, Korantzis I, Pectasides D, et al (2012). Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS). BMC Cancer, 12, 342. https://doi.org/10.1186/1471-2407-12-342
- Gautschi O, Mack PC, Davies AM, et al (2008). Pharmacogenomic approaches to individualizing chemotherapy for non-smallcell lung cancer: current status and new directions. Clin Lung Cancer, 9, S129-38. https://doi.org/10.3816/CLC.2008.s.019
- Hubner RA, Riley RD, Billingham LJ, et al (2011). Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS One, 6, e25164. https://doi.org/10.1371/journal.pone.0025164
- Jazieh AR, Bamefleh H, Demirkazik A, et al (2010). Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa region. J Natl Compr Canc Netw, 8, S16-21.
- Koh Y, Jang B, Han SW, et al (2010). Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol, 5, 320-5. https://doi.org/10.1097/JTO.0b013e3181ce684f
- Lee KH, Min HS, Han SW, et al (2008). ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer, 60, 401-7. https://doi.org/10.1016/j.lungcan.2007.10.014
- Leng XF, Chen MW, ssXian L, et al (2012). Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer Res, 31, 25. https://doi.org/10.1186/1756-9966-31-25
- Li XD, Han JC, Zhang YJ, et al (2013). Common variations of DNA repair genes are associated with response to platinumbased chemotherapy in NSCLCs. Asian Pac J Cancer Prev, 14, 145-8. https://doi.org/10.7314/APJCP.2013.14.1.145
- Li Y, Huang XE, Jin GF, et al (2011). Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751. Asian Pac J Cancer Prev, 12, 739-42.
- Maus MK, Mack PC, Astrow SH, et al (2013). Histology-Related Associations of ERCC1, RRM1, and TS Biomarkers in Patients with Non-Small-Cell Lung Cancer: Implications for Therapy. J Thorac Oncol, 8, 582-6.
- Pesta M, Kulda V, Fiala O, et al (2012). Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. Anticancer Res, 32, 5003-10.
- Santos ES, Blaya M, Raez LE (2009). Gene expression profiling and non-small-cell lung cancer: where are we now? Clin Lung Cancer, 10, 168-73. https://doi.org/10.3816/CLC.2009.n.023
- Vilmar A, Sorensen JB (2009). Excision repair crosscomplementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer, 64, 131-9. https://doi.org/10.1016/j.lungcan.2008.08.006
- Vilmar AC, Santoni-Rugiu E, Sorensen JB (2010). ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol, 21, 1817-24. https://doi.org/10.1093/annonc/mdq053
- Zhang ZY, Tian X, Wu R, et al (2012). Predictive role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy. Asian Pac J Cancer Prev, 13, 2583-6. https://doi.org/10.7314/APJCP.2012.13.6.2583
Cited by
- Analysis of ICU Treatment on Resection of Giant Tumors in the Mediastinum of the Thoracic Cavity vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3843
- Serum CEA Level Change and Its Significance Before and after Gefitinib Therapy on Patients with Advanced Non-small Cell Lung Cancer vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4205
- Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line vol.10, pp.4, 2014, https://doi.org/10.3892/mmr.2014.2440
- No Association between BRCA1 Immunohistochemical Expression and Tumor Grade, Stage or Overall Survival in Platinum-Treated Epithelial Ovarian Cancer Patients vol.15, pp.10, 2014, https://doi.org/10.7314/APJCP.2014.15.10.4275
- ERCC1 and BRCA1 mRNA expressions are associated with clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy vol.35, pp.5, 2014, https://doi.org/10.1007/s13277-014-1615-8
- Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3189
- Evaluation of Machine Learning Algorithm Utilization for Lung Cancer Classification Based on Gene Expression Levels vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.835
- in NSCLC vol.44, pp.1, 2016, https://doi.org/10.1177/0300060515607383
- Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer vol.17, pp.1, 2017, https://doi.org/10.1186/s12876-016-0561-x